SANOFI-AVENTIS (EPA:SAN)

BRIEF

published on 05/30/2025 at 07:05, 9 months 27 days ago

Itepekimab Reaches Primary Endpoint in COPD Phase 3 Study

Sanofi COPD Regeneron Itepekimab AERIFY-1
PRESS RELEASE

published on 05/30/2025 at 07:00, 9 months 27 days ago

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Itepekimab met primary endpoint in AERIFY-1 study for COPD, with significant reduction in exacerbations. AERIFY-2 did not meet endpoint. Sanofi and Regeneron assessing data for next steps

Sanofi COPD Regeneron Itepekimab AERIFY-1
BRIEF

published on 05/29/2025 at 14:35, 9 months 28 days ago

Positive impact of Beyfortus on hospitalizations due to RSV

Public Health Efficiency Beyfortus VRS Hospitalizations Childhood Vaccination
PRESS RELEASE

published on 05/29/2025 at 14:30, 9 months 28 days ago

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
Real-world comparison shows Beyfortus and RSVpreF immunization programs reduce infant RSV hospitalizations in Spain and UK. Beyfortus provides sustained protection against RSV with high efficacy and safety profile

RSV Beyfortus RSVpreF Infant Immunization
BRIEF

published on 05/22/2025 at 01:20, 10 months 4 days ago

Sanofi acquires Vigil Neuroscience to strengthen its Alzheimer's research

Acquisition Alzheimer's Disease Sanofi Neurology Vigil Neuroscience
PRESS RELEASE

published on 05/22/2025 at 01:15, 10 months 4 days ago

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
Sanofi acquires Vigil Neuroscience to enhance neurology pipeline with an investigational medicine for Alzheimer's disease. The acquisition includes VG-3927, a small molecule TREM2 agonist

Alzheimer's Disease Sanofi Neurology Vigil Neuroscience VG-3927
BRIEF

published on 05/15/2025 at 19:11, 10 months 10 days ago

Sanofi: Details on Voting Rights and Shares - April 2025

Voting Rights Actions Investment Sanofi April 2025
BRIEF

published on 04/30/2025 at 13:05, 10 months 26 days ago

Sanofi and CD&R finalize the sale of Opella

Sanofi CD&R Assignment Opella Consumer Health
PRESS RELEASE

published on 04/30/2025 at 13:00, 10 months 26 days ago

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creating global consumer healthcare leader. Sanofi's sale of a 50.0% stake to CD&R marks a strategic move with total net cash proceeds of around €10 billion

Transaction Sanofi CD&R Consumer Healthcare Opella
BRIEF

published on 04/08/2025 at 19:15, 11 months 17 days ago

Sanofi: Positive Publication of Tolebrutinib Data in NEJM

Multiple Sclerosis Sanofi Phase III NEJM Tolebrutinib

Published on 03/26/2026 at 14:05, 2 hours 16 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 3 hours 21 minutes ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 3 hours 21 minutes ago

GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 3 hours 22 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 3 hours 36 minutes ago

Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia

View all ACCESSWIRE

Published on 03/26/2026 at 15:25, 56 minutes ago

Duck Creek Loss Control Named 2026 Insurance Luminary Finalist by PropertyCasualty360
Published on 03/26/2026 at 15:23, 57 minutes ago

Sartorius AG - Resolutions of the Annual General Meeting
Published on 03/26/2026 at 15:05, 1 hour 16 minutes ago

JOY GROUP Announces 2025 Financial Results, Revenue Surpasses US$620M
Published on 03/26/2026 at 15:01, 1 hour 19 minutes ago

EQS-Adhoc: CENIT AG decides to switch from the Regulated Market (Prime Standard) to the Scale Segment of the Frankfurt Stock Exchange
Published on 03/26/2026 at 15:00, 1 hour 21 minutes ago

OLB’s financial performance remains at a consistently high level

View all EQS

Published on 03/26/2026 at 08:57, 7 hours 23 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 8 hours 51 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:53, 21 hours 28 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 21 hours 50 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 22 hours 36 minutes ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting

View all LES ECHOS COMFI WIRE

News